R-propranolol was shown to reduce the pro-angiogenic factor ANGPTL4 in a murine hemangioma model, without having beta-blocker activity and thus circumventing the potential side effects that could be caused by the beta-blocker activity of S-propranolol. This evidence concerns the gene ANGPTL4 and hemangioma.